X0306 4 2013-08-27 0 0001311596 Regado Biosciences Inc RGDO 0001189158 NEFF P SHERRILL CIRA CENTRE, 2929 ARCH STREET PHILADELPHIA PA 19104 1 0 1 0 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 399201 A 435129 I See Footnote 6 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 273468 A 708597 I See Footnote 6 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 465252 A 1173849 I See Footnote 6 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 48362 A 1222211 I See Footnote 6 Common Stock, par value $0.001 per share 2013-08-27 4 P 0 71810 4.00 A 1294021 I See Footnote 6 Stock Option (right to buy) 4.00 2013-08-27 4 A 0 17964 0 A 2023-08-27 Common Stock, par value $0.001 per share 17964 17964 D Series B Preferred Stock 2013-08-27 4 C 0 6666667 0 D Common Stock, par value $0.001 per share 399201 0 I See Footnote 6 Series C Preferred Stock 2013-08-27 4 C 0 4566908 0 D Common Stock, par value $0.001 per share 273468 0 I See Footnote 6 Series D Preferred Stock 2013-08-27 4 C 0 7769715 0 D Common Stock, par value $0.001 per share 465252 0 I See Footnote 6 Series E Preferred Stock 2013-08-27 4 C 0 807652 0 D Common Stock, par value $0.001 per share 48362 0 I See Footnote 6 100% of the shares underlying the option will vest on the one-year anniversary of the date of grant. The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The reportable securities are directly held by Quaker BioVentures, L.P. ("Quaker"). Quaker BioVentures Capital, L.P. ("Quaker Capital LP") is the general partner of the Quaker. Quaker BioVentures Capital, LLC ("Quaker Capital LLC") is the general partner of Quaker Capital LP and has voting and dispositive power over the shares held by Quaker. Voting and investment determinations made by Quaker Capital LLC with respect to the shares held by Quaker are made by an investment committee of Quaker Partners Management, L.P., which committee includes P. Sherrill Neff (the "Reporting Person"), a member of the board of the directors of the Company. The Reporting Person disclaims beneficial ownership of the securities held by Quaker, except to the extent of his pecuniary interest therein. /s/ P. Sherrill Neff by Christopher Courts, Attorney-in-Fact 2013-08-29